// Evidence Grader
Claim grades, A through F
Every major genomics claim in this course gets a transparent grade — from clinically established interventions to outright misleading marketing. Use this dashboard to audit what's settled, what's preliminary, and what's hype.
A
Clinically established
B
Supported, context-specific
C
Promising, preliminary
D
Plausible, unproven
E
Popular, weak support
F
Misleading or false
Filtered:← Back to module
A
HLA-B*57:01 screening before abacavir prevents hypersensitivity reactions
PREDICT-1 (NEJM 2008); now standard of care.
Module 04 · Pharmacogenomics in Practice →A
DPYD genotyping before fluoropyrimidine chemotherapy reduces grade ≥3 toxicity
Henricks Lancet Oncol 2018; EMA mandate 2020.
Module 04 · Pharmacogenomics in Practice →A
Pre-emptive multi-gene PGx testing reduces clinically relevant adverse drug reactions
PREPARE trial, Lancet 2023, ~30% relative reduction.
Module 04 · Pharmacogenomics in Practice →B
CYP2D6 genotype-guided dosing improves outcomes for SSRIs
Improves tolerability and time-to-remission in some RCTs (GUIDED, IMPACT); effect modest and population-dependent.
Module 04 · Pharmacogenomics in Practice →F
MTHFR genotyping is clinically useful for thrombosis or psychiatric workups
ACMG explicitly recommends against; no clinical utility.
Module 04 · Pharmacogenomics in Practice →